International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2017

We are pleased to announce the 10th edition of the International Workshop on Pharmacology of Tuberculosis Drugs which is scheduled for 15 October 2017 in Atlanta, USA.

The treatment of Tuberculosis is increasingly becoming a challenge worldwide. All around the world experts in the field are involved in intensive research to be able to cope with the various concerns with regard to treatment.

The aim of this abstract-driven workshop is to make a significant contribution to the optimization of TB treatment, by bringing experts together and having them present and discuss the latest important scientific findings in the TB clinical pharmacology field. Additionally, scientific, regulatory or strategy issues that are highly relevant to the optimization of TB treatment will be exchanged and discussed.

The format of the meeting will be a one-day workshop consisting of invited lectures, abstract presentations and roundtable discussions. Much time will be allocated to questions, answers and discussion in order to set up an intimate interactive workshop.

Topics that will be addressed include pharmacokinetics and pharmacodynamics of new TB drugs, Pharmacokinetics and pharmacodynamics of approved TB drugs, Pharmacokinetic – pharmacodynamic modeling, Drug-drug and drug-disease internactions, New TB drug development tools, new developments in pediatric TB, interactions between TB and HIV drugs, and treatment of MDR- and XDR-TB.

The target audience of this meeting consists of clinical pharmacologists, pharmacists, industry researchers, ID doctors, pediatricians, microbiologists, government representatives and other experts with an interest in clinical pharmacology.

General Information

Practical Information

The members of the Organizing Committee (OC) discuss, on a frequent basis, the scientific program of the workshop, identify interesting topics and candidate speakers and review all submitted abstracts.

The members of Scientific Committee assist the OC by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee actively participate in reviewing submitted abstracts.

• Jan-Willem Alffenaar, PhD, PharmD UMCG, The Netherlands
• Deron Burton CDC, USA
• Dakshina Chilukuri, PhD FDA, USA
• Véronique Dartois, PhD Rutgers, The State University of New Jersey, Newark, USA
• Paolo Denti, PhD University of Cape Town, South Africa
• Kelly Dooley, MD, PhD Johns Hopkins University, USA
• Tawanda Gumbo, MD Baylor Institute for Immunology Research, USA
• Richard Hafner, MD National Institutes of Health, USA
• Scott Heysell, MD, MPH University of Virginia, USA
• Anneke Hesseling, MD Desmond Tutu Tuberculosis Centre, South Africa
• Russell Kempker, MD, MSc Emory University School of Medicine, USA
• Steven Kern, PhD Bill & Melinda Gates Foundation, USA
• Christian Lienhardt, MD, PhD WHO – Stop TB Department, Switzerland
• Rovina Ruslami, MD, PhD Padjadjaran University, Indonesia
• Ulrika Simonsson, PharmD, PhD Uppsala University, Sweden
• Susan Swindells, MBBS University of Nebraska Medical Center, USA
• Andrew Vernon, MD CDC, TBTC, USA
• Robert Wallis, MD, FIDSA The Aurum Institute, South Africa